These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28581397)

  • 1. Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma.
    Sommat K; Ong WS; Hussain A; Soong YL; Tan T; Wee J; Fong KW
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):574-580. PubMed ID: 28581397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid V40 is a good predictor for subclinical hypothyroidism in patients with nasopharyngeal carcinoma after intensity modulated radiation therapy: a randomized clinical trial.
    Xu Y; Peng H; Su G; Cheng Y; Guo Q; Guo L; Peng XE; Ke J
    Radiat Oncol; 2023 Aug; 18(1):141. PubMed ID: 37626342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid V
    Zhou L; Chen J; Shen W; Chen ZL; Huang S; Tao CJ; Chen M; Yu ZH; Chen YY
    Radiat Oncol; 2020 Mar; 15(1):68. PubMed ID: 32293496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid dose-volume thresholds for the risk of radiation-related hypothyroidism in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy-A single-institution study.
    Huang CL; Tan HW; Guo R; Zhang Y; Peng H; Peng L; Lin AH; Mao YP; Sun Y; Ma J; Tang LL
    Cancer Med; 2019 Nov; 8(16):6887-6893. PubMed ID: 31560840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: Clinical and dosimetric predictors in a prospective cohort study.
    Zhai RP; Kong FF; Du CR; Hu CS; Ying HM
    Oral Oncol; 2017 May; 68():44-49. PubMed ID: 28438291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothalamic-pituitary-thyroid dysfunction induced by intensity-modulated radiotherapy (IMRT) for adult patients with nasopharyngeal carcinoma.
    Huang S; Wang X; Hu C; Ying H
    Med Oncol; 2013 Dec; 30(4):710. PubMed ID: 23999842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma.
    Lee V; Chan SY; Choi CW; Kwong D; Lam KO; Tong CC; Sze CK; Ng S; Leung TW; Lee A
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e52-60. PubMed ID: 27235379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer.
    Diaz R; Jaboin JJ; Morales-Paliza M; Koehler E; Phillips JG; Stinson S; Gilbert J; Chung CH; Murphy BA; Yarbrough WG; Murphy PB; Shyr Y; Cmelak AJ
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):468-76. PubMed ID: 19577867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin's lymphoma.
    Cella L; Conson M; Caterino M; De Rosa N; Liuzzi R; Picardi M; Grimaldi F; Solla R; Farella A; Salvatore M; Pacelli R
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1802-8. PubMed ID: 21514076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma survivors after intensity-modulated radiotherapy.
    Zhai R; Lyu Y; Ni M; Kong F; Du C; Hu C; Ying H
    Radiat Oncol; 2022 Mar; 17(1):57. PubMed ID: 35313921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: A dose-volume-outcome analysis.
    Li Y; Xu T; Qian W; Lu X; Hu C
    Oral Oncol; 2018 Sep; 84():1-6. PubMed ID: 30115466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of previously reported predictors for radiation-induced hypothyroidism in nasopharyngeal cancer patients treated with intensity-modulated radiation therapy, a post hoc analysis from a Phase III randomized trial.
    Lertbutsayanukul C; Kitpanit S; Prayongrat A; Kannarunimit D; Netsawang B; Chakkabat C
    J Radiat Res; 2018 Jul; 59(4):446-455. PubMed ID: 29750261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of radiation-induced thyroid gland changes in nasopharyngeal carcinoma patients in 48 months after radiotherapy.
    Lin Z; Yang Z; He B; Wang D; Gao X; Tam SY; Wu VWC
    PLoS One; 2018; 13(7):e0200310. PubMed ID: 29985952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.
    Tan T; Lim WT; Fong KW; Cheah SL; Soong YL; Ang MK; Ng QS; Tan D; Ong WS; Tan SH; Yip C; Quah D; Soo KC; Wee J
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):952-60. PubMed ID: 25832687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation-induced hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy with or without chemotherapy: Development of a nomogram based on the equivalent dose.
    Zhu MY; Wu HJ; Miao JJ; Di MP; Chen BY; Huang HG; Mai HQ; Wang L; Zhao C
    Oral Oncol; 2021 Sep; 120():105378. PubMed ID: 34174518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of early thyroid dysfunction after definitive radiotherapy in nasopharyngeal carcinoma patients.
    Lian CL; Zhuo RG; Zhou R; Yu YF; Zhou P; Lin Q; Wu SG
    Head Neck; 2023 Sep; 45(9):2344-2354. PubMed ID: 37415457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Wu M; Ou D; He X; Hu C
    Oral Oncol; 2017 Oct; 73():118-123. PubMed ID: 28939063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
    Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
    JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
    Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid V50 Highly Predictive of Hypothyroidism in Head-and-Neck Cancer Patients Treated With Intensity-modulated Radiotherapy (IMRT).
    Sachdev S; Refaat T; Bacchus ID; Sathiaseelan V; Mittal BB
    Am J Clin Oncol; 2017 Aug; 40(4):413-417. PubMed ID: 25503434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.